SAB Biotherapeutics Inc [SABS] stock prices are up 8.14% to $2.79 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SABS shares have gain 31.60% over the last week, with a monthly amount glided 39.50%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
SAB Biotherapeutics Inc [NASDAQ: SABS] stock has seen the most recent analyst activity on September 17, 2025, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $7. On October 09, 2024, Craig Hallum initiated with a Buy rating and assigned a price target of $11 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $12 on August 28, 2024. Chardan Capital Markets initiated its recommendation with a Buy and recommended $17 as its price target on November 05, 2021.
The stock price of SAB Biotherapeutics Inc [SABS] has been fluctuating between $1.00 and $6.60 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. SAB Biotherapeutics Inc [NASDAQ: SABS] shares were valued at $2.79 at the most recent close of the market. An investor can expect a potential return of 150.9% based on the average SABS price forecast.
Analyzing the SABS fundamentals
The SAB Biotherapeutics Inc [NASDAQ:SABS] reported sales of 0.11M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 7978.78% with Operating Profit Margin at 102005.03%, Pretax Profit Margin comes in at 90378.71%, and Net Profit Margin reading is 90378.71%. To continue investigating profitability, this company’s Return on Assets is posted at -1.23, Equity is -1.54 and Total Capital is -2.15. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.53.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that SAB Biotherapeutics Inc [NASDAQ:SABS]’s Current Ratio is 0.87. As well, the Quick Ratio is 0.87, while the Cash Ratio is 0.35. Considering the valuation of this stock, the price to sales ratio is 264.06, the price to book ratio is 2.16.
